Physician profile
Rachel E Thomas
NPI 1164564126
$1,571.72
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,572.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $202.34 | 2019 | |
| Akcea Therapeutics, INC. | $181.69 | 2019 | |
| Novo Nordisk INC | $139.02 | 2019 | |
| Merck Sharp & Dohme LLC | $122.58 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $110.82 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $95.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $84.92 | 2019 | |
| Abbvie INC. | $83.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $67.14 | 2019 | |
| Pfizer INC. | $63.85 | 2019 | |
| Lilly USA, LLC | $55.61 | 2019 | |
| Amarin Pharma, INC. | $52.76 | 2019 | |
| Grifols USA, LLC | $49.75 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.12 | 2019 | |
| Arbor Pharmaceuticals, INC. | $43.10 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $36.46 | 2019 | |
| Sanofi-Aventis U.S. LLC | $25.49 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $22.86 | 2019 | |
| Astellas Pharma US INC | $19.96 | 2019 | |
| Dynavax Technologies Corporation | $16.79 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.41 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.08 | 2019 | |
| Glaxosmithkline, LLC. | $13.75 | 2019 | |
| Gilead Sciences, INC. | $12.12 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.